bermekimab
-
Janssen Pharmaceutical Finalizes $750M Acquisition of Rights to XBiotech’s New Drug Candidate for Multiple Dermatological Conditions
Janssen Pharmaceutical of Johnson & Johnson, with a research campus in Spring House, has finalized its $750 million acquisition of…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
